Anti-Rheumatic Drugs - Saudi Arabia

In Saudi Arabia, the Anti-Rheumatic Drugs market is expected to witness significant growth in the coming years.
The projected revenue for this market is estimated to reach US$140.50m in 2024.
Moreover, a steady annual growth rate of 0.32% is anticipated from 2024 to 2029, leading to a market volume of US$142.80m by the end of 2029.
When compared globally, United States is expected to generate the highest revenue in the Anti-Rheumatic Drugs market, with a staggering US$34.70bn in 2024.
In Saudi Arabia, the demand for anti-rheumatic drugs is increasing due to the high prevalence of rheumatoid arthritis in the population.

Definition:
The market Anti-Rheumatic Drugs includes medication for the treatment of the inflammatory disease rheumatism. Due to the high prevalence of rheumatism and the large size of the market, this section of immune diseases is treated as a separate market. Both steroidal and non-steroidal anti-rheumatics are included. Disease-modifying rheumatic drugs (DMARDs), such as tumor necrosis factor inhibitors (a type of biologic DMARD), are particularly important in terms of commerciality.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: AbbVie, Johnson & Johnson, Pfizer, Amgen, Roche

Drugs to treat rheumatism
Steroidal (corticosteroids) and non-steroidal anti-rheumatics
Disease-modifying antirheumatic drugs (DMARDs)
Tumor necrosis factor (TNF) inhibitors

Drugs to treat other autoimmune diseases (such as multiple sclerosis or psoriasis)
Analgetics for general use (such as paracetamol)
Treatment of osteoarthritis

Anti-Rheumatic Drugs market in Saudi Arabia has been experiencing significant growth in recent years.

Customer preferences: The increasing prevalence of rheumatoid arthritis and other autoimmune diseases have been driving the demand for anti-rheumatic drugs in Saudi Arabia. Patients are seeking effective treatment options that can alleviate their symptoms and improve their quality of life. In addition, the rising awareness about the benefits of early diagnosis and treatment has led to an increase in demand for anti-rheumatic drugs.

Trends in the market: The Saudi Arabian government has been investing heavily in the healthcare sector, which has contributed to the growth of the anti-rheumatic drugs market. The government has been focusing on improving the quality of healthcare services and expanding the healthcare infrastructure to meet the growing demand. This has led to an increase in the availability of anti-rheumatic drugs in the country.

Local special circumstances: Saudi Arabia has a high prevalence of rheumatoid arthritis, which is one of the major drivers of the anti-rheumatic drugs market. According to a study conducted by the Saudi Society for Rheumatology, the prevalence of rheumatoid arthritis in Saudi Arabia is higher than the global average. This has led to an increase in demand for anti-rheumatic drugs in the country.

Underlying macroeconomic factors: The Saudi Arabian economy has been growing steadily, which has contributed to the growth of the healthcare sector. The government has been investing heavily in the healthcare sector, which has led to an increase in the availability of healthcare services and anti-rheumatic drugs. In addition, the rising disposable income and increasing healthcare expenditure of the population have also contributed to the growth of the anti-rheumatic drugs market.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.